DURECT Corporation (DRRX)
NASDAQ: DRRX · Real-Time Price · USD
0.6592
-0.0408 (-5.83%)
Apr 25, 2025, 4:00 PM EDT - Market closed
DURECT Revenue
In the year 2024, DURECT had annual revenue of $2.03M, down -21.58%. DURECT had revenue of $453.00K in the quarter ending December 31, 2024.
Revenue (ttm)
$2.03M
Revenue Growth
-21.58%
P/S Ratio
10.20
Revenue / Employee
$96,714
Employees
21
Market Cap
20.46M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.03M | -559.00K | -21.58% |
Dec 31, 2023 | 2.59M | -16.69M | -86.57% |
Dec 31, 2022 | 19.28M | 5.31M | 37.96% |
Dec 31, 2021 | 13.98M | -16.13M | -53.58% |
Dec 31, 2020 | 30.11M | 5.04M | 20.09% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
DRRX News
- 4 weeks ago - DURECT Corporation (DRRX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - PRNewsWire
- 5 weeks ago - DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update - PRNewsWire
- 2 months ago - DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - PRNewsWire
- 3 months ago - DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence - PRNewsWire
- 5 months ago - DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million - PRNewsWire
- 5 months ago - DURECT Corporation (DRRX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update - PRNewsWire